TrianglePUBLICATIONS · 31178155
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Lancet
- Publication date
- 2019 Jun 29
- First author
- Pivot X
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Pivot X
- type
- Author
- name
- Romieu G
- type
- Author
- name
- Debled M
- type
- Author
- name
- Pierga JY
- type
- Author
- name
- Kerbrat P
- type
- Author
- name
- Bachelot T
- type
- Author
- name
- Lortholary A
- type
- Author
- name
- Espié M
- type
- Author
- name
- Fumoleau P
- type
- Author
- name
- Serin D
- type
- Author
- name
- Jacquin JP
- type
- Author
- name
- Jouannaud C
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Pivot X
- type
- Author
- name
- Romieu G
- type
- Author
- name
- Debled M
- type
- Author
- name
- Pierga JY
- type
- Author
- name
- Kerbrat P
- type
- Author
- name
- Bachelot T
- type
- Author
- name
- Lortholary A
- type
- Author
- name
- Espié M
- type
- Author
- name
- Fumoleau P
- type
- Author
- name
- Serin D
- type
- Author
- name
- Jacquin JP
- type
- Author
- name
- Jouannaud C
- type
- Author
- bibliography ids
- nci-bib-d973b770643d913fec981ade
- book metadata
- content sha256
- 0610d3df14da9d7fcdd5e163e2566af9467bee262370721448ea684f7a939ed2
- document type
- citation
- dois
- 10.1016/S0140-6736(19)30653-1
- electronic publication date
- display
- 2019 Jun 6
- precision
- day
- year
- 2019
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:31178155
- immutable id
- pubmed:31178155@0610d3df14da9d7fcdd5e163e2566af9467bee262370721448ea684f7a939ed2
- journal
- abbreviation
- Lancet
- issn electronic
- 1474-547X
- issn print
- 0140-6736
- issue
- 10191
- name
- Lancet (London, England)
- nlm unique id
- 2985213R
- pages
- 2591-2598
- volume
- 393
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 31178155
- provenance
- batch id
- 23ffe1e2a9e160b6dca0
- provider
- NCBI PubMed ESummary
- record sha256
- 3bf22c56f0ab0b48980b1d8d3d3c9c17f57164e2e8592d309ad99d00e764bed2
- response sha256
- d5cbfde8f87ba85b214c53aaf0e8fa33d70fec48dd4fde7745538180cd7e1841
- retrieved at
- 2026-09-09T23:47:44.690737+00:00
- publication date
- display
- 2019 Jun 29
- precision
- day
- year
- 2019
- publication types
- Clinical Trial, Phase III
- Comparative Study
- Equivalence Trial
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
Preserved source evidence · Not medical advice